125 related articles for article (PubMed ID: 38299675)
1. Membrane-bound CD95 ligand modulates CD19-mediated B cell receptor signaling and EBV activation.
Liu M; Huang C; Zhou X; Jiang C; Liu S; Gao Y; Kuang L; Lei Z; Jia R; Xu J; Legembre P; Liang X
J Med Virol; 2024 Feb; 96(2):e29440. PubMed ID: 38299675
[TBL] [Abstract][Full Text] [Related]
2. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.
Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J
Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis.
Wilson AD; Redchenko I; Williams NA; Morgan AJ
Int Immunol; 1998 Aug; 10(8):1149-57. PubMed ID: 9723701
[TBL] [Abstract][Full Text] [Related]
4. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.
Le Clorennec C; Ouk TS; Youlyouz-Marfak I; Panteix S; Martin CC; Rastelli J; Adriaenssens E; Zimber-Strobl U; Coll J; Feuillard J; Jayat-Vignoles C
J Virol; 2008 Jul; 82(13):6721-33. PubMed ID: 18448526
[TBL] [Abstract][Full Text] [Related]
6. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
7. CD19 signalling improves the Epstein-Barr virus-induced immortalization of human B cell.
Hur DY; Lee MH; Kim JW; Kim JH; Shin YK; Rho JK; Kwack KB; Lee WJ; Han BG
Cell Prolif; 2005 Feb; 38(1):35-45. PubMed ID: 15679865
[TBL] [Abstract][Full Text] [Related]
8. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Front Immunol; 2023; 14():878953. PubMed ID: 37033971
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases.
Wilkie GM; Taylor C; Jones MM; Burns DM; Turner M; Kilpatrick D; Amlot PL; Crawford DH; Haque T
J Immunother; 2004; 27(4):309-16. PubMed ID: 15235392
[TBL] [Abstract][Full Text] [Related]
10. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
11. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
[TBL] [Abstract][Full Text] [Related]
12. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
[TBL] [Abstract][Full Text] [Related]
13. CD95 Signaling Inhibits B Cell Receptor-Mediated Gammaherpesvirus Replication in Apoptosis-Resistant B Lymphoma Cells.
Tan L; Zhang C; Dematos J; Kuang L; Jung JU; Liang X
J Virol; 2016 Nov; 90(21):9782-9796. PubMed ID: 27558422
[TBL] [Abstract][Full Text] [Related]
14. EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Chen A; Zhao B; Kieff E; Aster JC; Wang F
J Virol; 2006 Oct; 80(20):10139-50. PubMed ID: 17005691
[TBL] [Abstract][Full Text] [Related]
15. Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(-) fetal liver cells.
Bárcena A; Muench MO; Song KS; Ohkubo T; Harrison MR
Exp Hematol; 1999 Sep; 27(9):1428-39. PubMed ID: 10480434
[TBL] [Abstract][Full Text] [Related]
16. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders.
Ouyang J; Juszczynski P; Rodig SJ; Green MR; O'Donnell E; Currie T; Armant M; Takeyama K; Monti S; Rabinovich GA; Ritz J; Kutok JL; Shipp MA
Blood; 2011 Apr; 117(16):4315-22. PubMed ID: 21300977
[TBL] [Abstract][Full Text] [Related]
17. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
[TBL] [Abstract][Full Text] [Related]
19. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
20. EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis.
Snow AL; Vaysberg M; Krams SM; Martinez OM
Am J Transplant; 2006 May; 6(5 Pt 1):976-85. PubMed ID: 16611333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
